Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $31 price target.
EF Hutton analyst Jason Kolbert maintains Clene (NASDAQ:CLNN) with a Buy and maintains $23 price target.
EF Hutton analyst Jason Kolbert initiates coverage on Clene (NASDAQ:CLNN) with a Buy rating and announces Price Target of $23.
HC Wainwright & Co. analyst Joseph Pantginis maintains Clene (NASDAQ:CLNN) with a Buy, adjusts target to $31 from $7 (1-20 ...
Clene (NASDAQ:CLNN) reported quarterly losses of $(1.06) per share which beat the analyst consensus estimate of $(1.49) by 28.8...
Canaccord Genuity analyst Sumant Kulkarni reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $94 price target.
CNM-Au8 treated participants in the HEALEY ALS Platform Trial with substantial neurofilament light (NfL) declines (CNM-Au8 NfL ...
